Multiple Growth Factor Targeting by Engineered Insulin-like Growth Factor Binding Protein-3 Augments EGF Receptor Tyrosine Kinase Inhibitor Efficacy

Resistance to cancer therapy is a challenge because of innate tumor heterogeneity and constant tumor evolution. Since the pathway of resistance cannot be predicted, combination therapies may address this progression. We discovered that in addition to IGF1 and IGF2, IGFBP-3 binds bFGF, HGF, neureguli...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Elizabeth A., Chen, Wan-Yu, Wong, Chi-Huey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026407/
https://www.ncbi.nlm.nih.gov/pubmed/32066763
http://dx.doi.org/10.1038/s41598-020-59466-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026407/
https://www.ncbi.nlm.nih.gov/pubmed/32066763
http://dx.doi.org/10.1038/s41598-020-59466-6

Ejemplares similares